Table 1 Baseline characteristics of trial participants

Age (years)

63

8

Height (m)

1.72

0.13

Body mass (kg)

80.4

31.4

BMI (kg/m²)

27.3

8.7

M-protein (g/L, N = 14)

13.4

8.6

FLC ratio

  Overall

4.44

12.50

  Involved kappa FLC (N = 9)

10.25

17.56

  Involved lambda FLC (N = 4)

0.09

0.04

  Normal FLC ratio (N = 2)

1.01

0.01

N

Percentage

Sex

  Male

8

53

  Female

7

47

Diagnosis

  MGUS

3

20

  SMM

12

80

Isotype

  MGUS IgG Kappa

1

7

  MGUS IgG Lambda

1

7

  MGUS Bi-clonal IgA Kappa

1

7

  SMM IgG Kappa

5

33

  SMM IgG Lambda

3

20

  SMM IgA Kappa

2

13

  SMM Bi-clonal IgA Lambda + IgG Lambda

1

7

  SMM Kappa light chain only

1

7

Risk stratification

  MGUS High-intermediate risk¹

1

7

  MGUS Low-intermediate risk¹

1

7

  MGUS Low risk¹

1

7

  SMM High risk²

3

20

  SMM Intermediate risk²

3

20

  SMM Low risk²

6

40

Immunoparesis

  Affecting one polyclonal immunoglobulin

5

33

  Affecting two polyclonal immunoglobulins

5

33

  Affecting three polyclonal immunoglobulins

1

7

  Immunoparesis not evident

4

27

Ethnicity

  White

14

93

  Mixed/multiple

1

7

Employment status

  Employed

10

67

  Retired

4

27

  Unable to work

1

7

Smoking status

  Never-smoker

10

67

  Ex-smoker

5

33

BMI category

  Healthy (< 25 kg/m²)

5

33

  Overweight (25-29.9 kg/m²)

5

33

  Obese (> 30 kg/m²)

5

33

Physical activity level

  High (PAL ≥ 1.75)

8

53

  Low (PAL < 1.75)

7

47